ARO-APOC3

APOC3 antisense oligonucleotide · Arrowhead Pharmaceuticals

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for ARO-APOC3, covering 2025-12-17 to 2026-03-24. Get the full timeline:

Most recent: Clinical Trial Update: Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia [Phase 2]